A common clinical situation involves signs or symptoms suggesting a disorder which may or may not be malignant. While neither AMAS nor any other clinical laboratory test can by itself answer this question, AMAS test results may help the physician in the diagnostic process.
The double-blind clinical studies in the graph on the next page include non-cancer control groups and malignancies of the breast, lung, and brain as well as melanomas, lymphomas, leukemias, and colorectal malignancies.
Also included are smaller numbers of malignancies of the larynx, uterus, cervix, ovary, anus, stomach, esophagus, prostate, bladder, urethra, kidney, testis, thyroid, and skin
and fibrosarcoma, leiomyosarcoma, osteogenic sarcoma, rhabdomyosarcoma, mesothelioma, liposarcoma, and hemangioblastoma
Click here to view Multi-Center Studies graph.
Please ask your doctor. Physicians around the country are recommending and administering the AMAS test on a regular basis for patients at high risk for cancer, and for follow-up purposes on patients already diagnosed and/or treated for cancer. Physician authorization is required for the AMAS Test.
If your doctor is not familiar with the test and does not have a shipping kit, please call and we can send a free kit.
The kit contains reprints of scientific papers on the test, a requisition form, and all supplies for drawing and sending a blood serum sample. The kit includes a styrofoam packing box and silicone-free test tubes, as well as step-by-step instructions for the lab. The only other requirements are a centrifuge and a local supplier of dry ice for shipping. Your doctor should receive the results within 72 hours of our receiving the serum sample.
The low false-positive and false-negative rates have permitted successful detection in selected high-risk populations, as in chemical workers (ref 08) and in the preclinical detection of cancer in 2.3 percent of medical-surgical cases (ref 04) but the efficacy of detection in larger normal populations has yet to be determined.
A low AMA level can occur in non-cancer, in advanced and terminal cancer, and in successfully treated cancer in which there is no further evidence of disease; clinical status must be used to distinguish these states.
As in all clinical laboratory tests, the AMAS test is not by itself diagnostic of the presence of absence of disease, and its results can only be assessed as an aid to diagnosis, detection or monitoring of disease in relation to the history, medical signs, and symptoms and the overall condition of the patient.
If repeat determinations agree, the false-positive and false negative rates are less than 1% (specificity and sensitivity greater than 99%); in single determinations, false positives are 5% and false negatives 7% (3,315 double-blind tests of patients and controls, (ref.4,6, and 8)); AMAS antibody, determined in this test, tends to be detected earlier than antigens, and is of potental help in early detection.
However, since antibody fails terminally the test cannot be used as a diagnostic aid late in the disease. The level of AMAS is quantitatively related to survival in known cancer patients; the higher the level of AMAS the longer the predicted survival.
As in all clinical laboratory tests, the AMAS Test is not by itself diagnostic of the presence or absence of disease, and its results can only be assessed as an aid to diagnosis, detection or monitoring of disease in relation to the history, medical signs and symptoms and the overall condition of the patient.
The AMAS test is covered by standard Medicare reimbursement to Oncolab. While we do not work directly with private insurers, or HMOs, we can provide you with a receipt which you may be able to use to get reimbursement from your provider.